CDP 1050Alternative Names: CDP-1050
Latest Information Update: 07 Jan 2011
At a glance
- Originator Duke University; Johns Hopkins University
- Developer Cordex Pharma
- Class Heart failure therapies
- Mechanism of Action Nitric oxide donors; Reactive oxygen species inhibitors; Ryanodine receptor calcium release channel modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Heart failure
Most Recent Events
- 20 Feb 2009 Phase-I clinical trials in Heart failure in USA (unspecified route)